SPONSOR

The First Affiliated Hospital with Nanjing Medical University

Total Trials

Recruiting

Phases

EARLY_Phase 1, Phase 2, Phase 4

Conditions studied: Multiple Myeloma Marginal Zone Lymphoma(MZL)Antisynthetase Syndrome Rheumatoid Arthritis TNBC Adjuvant Therapy Lymph Node Positive Social Isolation SCD Subjective Cognitive Decline

The First Affiliated Hospital with Nanjing Medical University is a clinical research sponsor with 25 registered studies on ClinicalTrials.gov, of which 25 are actively recruiting participants. Research covers conditions including Multiple Myeloma, Marginal Zone Lymphoma(MZL), Antisynthetase Syndrome, Rheumatoid Arthritis.

The trial portfolio spans EARLY_Phase 1, Phase 2, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — The First Affiliated Hospital with Nanjing Medical University

How many clinical trials has The First Affiliated Hospital with Nanjing Medical University sponsored?

ClinicalMetric currently tracks 25 clinical trials sponsored by The First Affiliated Hospital with Nanjing Medical University, of which 25 are actively recruiting participants. These trials cover conditions including Multiple Myeloma, Marginal Zone Lymphoma(MZL), Antisynthetase Syndrome. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does The First Affiliated Hospital with Nanjing Medical University research focus on?

The First Affiliated Hospital with Nanjing Medical University clinical trials span Multiple Myeloma, Marginal Zone Lymphoma(MZL), Antisynthetase Syndrome, Rheumatoid Arthritis, TNBC, and additional conditions. The research pipeline includes EARLY_Phase 1, Phase 2, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a The First Affiliated Hospital with Nanjing Medical University clinical trial?

To participate in a The First Affiliated Hospital with Nanjing Medical University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The First Affiliated Hospital with Nanjing Medical University trials with current recruitment status updated daily.

The First Affiliated Hospital with Nanjing Medical University

Frequently Asked Questions — The First Affiliated Hospital with Nanjing Medical University

Clinical Trials by The First Affiliated Hospital with Nanjing Medical University

A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis

A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.

The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

VA Dual Sequential Therapy

High Resolution Diffusion Weighted Imaging in Prostate

Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy

A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology

Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy

Immunotherapy for Hepatocellular Carcinoma

Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease

Impact of Pet Cats on Nasal and Gut Microbiota in Patients With Cat Allergen Allergy

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Study on the Optimization of the Diagnostic Process for Chronic Rhinitis Using Nasal Allergen Provocation Test

Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field

Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion

Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC

Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT